Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | GLI1 | P08151 | 1/20 | 0.64 |
| ▸ | GLI2 | P10070 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27598564 | 1.00 | PTGS1 (0.65) | PTGS1GLI1GLI2MEN1CYP2D6 | |
| SCHEMBL13679147 | 0.84 | GLI1 (0.68) | PTGS1GLI1GLI2MEN1CYP2D6 | |
| SCHEMBL11533724 | 0.83 | PTGS1 (0.60) | PTGS1GLI1GLI2MEN1CYP2D6 | |
| SCHEMBL11533548 | 0.83 | GLI1 (0.81) | PTGS1GLI1GLI2MEN1CYP2D6 | |
| SCHEMBL9878055 | 0.83 | PTGS1 (0.72) | PTGS1GLI1GLI2MEN1CYP2D6 | |
| SCHEMBL11531868 | 0.83 | PTGS1 (0.72) | PTGS1GLI1GLI2MEN1CYP2D6 | |
| SCHEMBL6137585 | 0.82 | MME (0.62) | MEN1KMT2APTGS2MMELMNA | |
| SCHEMBL11533087 | 0.82 | GLI1 (0.59) | PTGS1GLI1GLI2MEN1CYP2D6 | |
| SCHEMBL3147315 | 0.81 | MME (0.51) | GLI1GLI2PTGS2MMELMNA | |
| SCHEMBL12608944 | 0.81 | GLI1 (0.64) | PTGS1GLI1GLI2MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939521-B2 | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them | DompePHA.R.MA S.p.A. (IT) | 2011-05-10 | — | — | US | claimed |
| EP-1856031-B1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-02-25 | — | — | EP | claimed |
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | disclosed |
| CN-100513386-C | Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils | DOMP S P A (IT) | 2009-07-15 | — | — | CN | disclosed |
| EP-1856031-B1 | 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-02-25 | — | — | EP | disclosed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| CN-1479715-A | Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils | ��ķ�ɷ�����˾ | 2004-03-03 | — | — | CN | disclosed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | CXCL8, MMP8, CCR8 | PTGS1 171/4885GLI1 886/4885GLI2 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.